Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Br J Clin Pharmacol ; 89(7): 2283-2294, 2023 07.
Article in English | MEDLINE | ID: mdl-36854898

ABSTRACT

AIMS: Dose-banding (DB) consists in approximating the theoretical dose of anticancer drugs calculated according to the body surface area (Dose-BSA) of patients. This concept is supported by pharmacokinetic but not by clinical data. The aim of this study was to assess the clinical outcome of DB defined as dose-fitting up to ±10%. METHODS: This was a retrospective study conducted in patients receiving weekly paclitaxel in neoadjuvant (NAT) and metastatic (M+) settings. Three groups of patients were considered according to type of paclitaxel dosing: Dose-BSA, DB approximated down (DB-Low) and DB approximated up (DB-High). Efficacy was evaluated by the rate of pathological complete response for patients in NAT setting and by the median of progression-free survival plus overall survival for those in M+ setting. Toxicity and efficacy were compared in the 3 groups. RESULTS: A total of 224 and 209 patients were assessable in the M+ and NAT settings, respectively. A toxic event was observed for 31.7 and 27.3% in M+ and NAT, respectively. The rate of pathological complete response was 41.6% in NAT. The median progression-free survival was 5.2 (4.1-5.8) months and overall survival was 16.3 (14.6-18.4) months for patients in M+. Efficacy and toxicity were not different in DB-Low and DB-High groups compared to Dose-BSA group. CONCLUSION: DB with approximated doses up to ±10% does not seem to influence clinical outcome of patients treated with weekly paclitaxel. This is the first study to include clinical observations, which lends support to DB as a safe and effective dosing method.


Subject(s)
Antineoplastic Agents , Breast Neoplasms , Humans , Female , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Paclitaxel/adverse effects , Retrospective Studies , Antineoplastic Agents/therapeutic use , Progression-Free Survival , Antineoplastic Combined Chemotherapy Protocols/adverse effects
2.
Cancer Chemother Pharmacol ; 87(4): 579-583, 2021 04.
Article in English | MEDLINE | ID: mdl-33587160

ABSTRACT

We report the case of a 44-year-old patient who experienced severe toxicity while being treated with capecitabine at standard dose for metastatic breast cancer. As the patient had already received 5-FU within the FEC protocol (5-FU 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2) 10 years ago without experiencing any severe adverse event, no DPD deficiency testing was performed before capecitabine treatment. Nevertheless, she experienced severe diarrhea and grade 2 hand-foot syndrome from the first cycle, forcing her to stop the treatment. Phenotypic and genotypic investigation of DPD activity revealed that the patient had a partial deficiency and had therefore been exposed to a higher risk of developing severe toxicities on fluoropyrimidines. This case proves that tolerance to low-dose fluoropyrimidines does not preclude DPD deficiency and the occurrence of severe toxicities if higher doses of fluoropyrimidines are used as a second-line treatment. It emphasizes the role of DPD phenotyping testing based on uracilemia in patients scheduled for fluoropyrimidine drugs, even if previous courses with low-dose 5-FU were safely administered.


Subject(s)
Breast Neoplasms/drug therapy , Capecitabine/adverse effects , Dihydropyrimidine Dehydrogenase Deficiency/complications , Fluorouracil/adverse effects , Adult , Female , Humans
3.
Support Care Cancer ; 28(1): 185-192, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31001691

ABSTRACT

PURPOSE: The objective of our study was to assess the rate of work adjustments 1 year after the diagnosis in a population of female breast cancer (BC) survivors, in the context of the French system of social protection. We also characterised these adjustments and their influence on the reduction of professional exclusion of patients 1 year after the diagnosis. METHODS: This observational, prospective study was conducted from February 2015 to April 2016 among female patients with BC. Inclusion criteria were women aged between 18 and 65 years, treated for BC and integrated into the labour market at the time of diagnosis (working or on sick leave). Exclusion criteria were metastatic BC, retired patients and refusal to participate. A 1-year follow-up was scheduled, and data collection was performed with questionnaires. RESULTS: In total, 213 patients were included between February 2015 and April 2016. One year after the diagnosis (T1), among 185 BC survivors, 78 (42.2%) patients were working. Among them, 13 patients did not interrupt their occupational activity and 65 returned to work after a period of sick leave. Sixty-four patients returned to work after the end of chemotherapy (after 6 months), and one returned to work before this therapeutic threshold. Sixty-six patients (35.7%) benefited from at least one adjustment of their work conditions to facilitate their return to work (RTW) or maintenance at work: working hours were decreased for 43 patients, and workstation changes were performed for 22 patients. An occupational health physician was involved for some patients; work adjustments were prescribed to 42 patients, 7 patients had medical restrictions for physical reasons and 4 patients had restrictions for psychological reasons. Forty-three patients benefited from part-time work prescribed for therapeutic reasons. CONCLUSIONS: Referral to occupational health physicians and work adjustments remain limited in the process of RTW or maintenance at work after BC in France, despite their positive impact.


Subject(s)
Breast Neoplasms/epidemiology , Cancer Survivors/statistics & numerical data , Return to Work , Social Adjustment , Adaptation, Psychological/physiology , Adolescent , Adult , Aged , Breast Neoplasms/drug therapy , Breast Neoplasms/psychology , Breast Neoplasms/rehabilitation , Cancer Survivors/psychology , Employment/psychology , Employment/statistics & numerical data , Female , France/epidemiology , Humans , Middle Aged , Prospective Studies , Return to Work/psychology , Return to Work/statistics & numerical data , Sick Leave/statistics & numerical data , Surveys and Questionnaires , Young Adult
4.
Eur J Clin Pharmacol ; 74(9): 1181-1184, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29862427

ABSTRACT

BACKGROUND: Three studies have suggested a potential positive association between the use of tamoxifen in breast cancer and Parkinsonism, mainly after long-term exposure. OBJECTIVES: To explore this potential signal, we performed a case/non-case study using the World Health Organization Global Individual Case Safety Reports (ICSRs) database, VigiBase® between 1979 and 2018. METHODS: Among women ≥ 55 years, we measured the risk of reporting "Parkinsonism" compared with all other adverse drug reactions [as a reporting odds ratio (ROR 95% CI)] for tamoxifen compared to all other drugs or aromatase inhibitors. RESULTS: During the study period, 356 ICSRs of Parkinsonism reported with tamoxifen were identified. We failed to find a positive association between tamoxifen exposure and Parkinsonism in comparison with exposure to other drugs (ROR = 0.79; 95% CI 0.71-0.88) or aromatase inhibitors (ROR = 0.39; 95% CI 0.33-0.46). CONCLUSION: This study did not find evidence for Parkinsonism associated with tamoxifen.


Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Parkinson Disease, Secondary/chemically induced , Tamoxifen/adverse effects , Adverse Drug Reaction Reporting Systems , Databases, Factual , Female , Humans , Middle Aged , Parkinson Disease, Secondary/diagnosis , Pharmacovigilance , Retrospective Studies , Risk Assessment , Risk Factors , World Health Organization
5.
Bull Cancer ; 104(10): 869-874, 2017 Oct.
Article in French | MEDLINE | ID: mdl-29032944

ABSTRACT

New routes of administration available for some targeted therapies, especially subcutaneous injections, have an impact not only on the patients' daycare experience, but also on the unit's organization. This observational study conducted on 48 voluntary patients at the Institut universitaire du cancer Toulouse-Oncopole shows that the mean duration of the outpatient unit stay is diminished by one hour when a subcutaneous injection is used instead of an intravenous route. This duration decrease is mainly caused by an 82% average reduction in treatment duration. However, the waiting times before and after the treatment itself are not significantly impacted. Organizational methods related to the treatment prescription and preparation remain indeed the same. Anticipated prescription is not noticeably impacted either. This reduction of the duration of stay will truly be obtained if the whole unit's organization is adapted.


Subject(s)
Antineoplastic Agents/administration & dosage , Day Care, Medical/statistics & numerical data , Length of Stay/statistics & numerical data , Molecular Targeted Therapy/methods , Cancer Care Facilities/organization & administration , Cancer Care Facilities/statistics & numerical data , Day Care, Medical/organization & administration , Drug Compounding/statistics & numerical data , Humans , Injections, Intravenous/statistics & numerical data , Injections, Subcutaneous/statistics & numerical data , Molecular Targeted Therapy/statistics & numerical data , Outpatients , Time Factors
6.
J Vasc Access ; 18(5): 390-395, 2017 Sep 11.
Article in English | MEDLINE | ID: mdl-28731491

ABSTRACT

INTRODUCTION: Most cancer patients require a totally implanted central venous catheter (TIVAD) for their treatment. In a previous study, we developed and validated a questionnaire dubbed QASICC (Questionnaire for Acceptance of, and Satisfaction with, Implanted Central Venous Catheter) assessing patient satisfaction with, and acceptance of, their TIVAD. In the present study, we conducted a large, prospective, multicenter study in cancer patients aimed to analyze factors that could influence patients' acceptance of, and satisfaction with, their device. METHODS: The QASICC is composed of 22 items assessing 5 dimensions. The construction and validation of the questionnaire was achieved using validated methodology to determine its psychometric characteristics. The questionnaire was submitted to 720 patients in 11 French institutions; 567 answers were analyzed. RESULTS: Younger patients had the most difficulties in coping with their TIVAD, especially regarding daily activities and their body image and private life compared to older patients. Sex was significantly related to patient satisfaction, with worse scores in women. Breast tumor location was also correlated with low TIVAD acceptance. TIVAD on the right side also positively influenced satisfaction and acceptance of the device. CONCLUSIONS: QASICC has proved to be efficient, and to detect known issues regarding daily activities and body image. As our population was mostly composed of women with breast cancer, our results reflect specific aspects of this population. The TIVAD remains generally well-accepted and our questionnaire should help health-care workers to better address the specific needs of their patients based on the answers provided.


Subject(s)
Antineoplastic Agents/administration & dosage , Catheterization, Central Venous/instrumentation , Catheters, Indwelling , Central Venous Catheters , Neoplasms/drug therapy , Patient Acceptance of Health Care , Patient Satisfaction , Administration, Intravenous , Adult , Aged , Female , France , Humans , Male , Middle Aged , Neoplasms/diagnosis , Neoplasms/psychology , Prospective Studies , Psychometrics , Quality of Life , Surveys and Questionnaires , Young Adult
7.
Eur J Dermatol ; 26(5): 427-443, 2016 Oct 01.
Article in English | MEDLINE | ID: mdl-27550571

ABSTRACT

Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.


Subject(s)
Antineoplastic Agents/adverse effects , Drug Eruptions/etiology , Paclitaxel/adverse effects , Taxoids/adverse effects , Alopecia/chemically induced , Docetaxel , Edema/chemically induced , Humans , Lupus Erythematosus, Cutaneous/chemically induced , Nail Diseases/chemically induced , Pigmentation Disorders/chemically induced , Radiodermatitis/chemically induced
8.
Rev Infirm ; (213): 37-9, 2015.
Article in French | MEDLINE | ID: mdl-26365645

ABSTRACT

An innovative scheme has been operational since 2013 at the Institut Claudius Regaud in Toulouse, aimed at patients undergoing chemotherapy. After an initial consultation, patients receive regular telephone support at home from expert nurses between treatments. The scheme helps to improve patient management and reinforce the community-hospital link.


Subject(s)
Neoplasms/drug therapy , Neoplasms/nursing , Telenursing , France , Humans
9.
Bull Cancer ; 102(4): 301-15, 2015 Apr.
Article in French | MEDLINE | ID: mdl-25799876

ABSTRACT

OBJECTIVE: Most cancer patients require a totally-implanted central venous access device (TIVAD) for their treatment. This was a prospective, multicenter, open study to: (i) develop and validate a French-language questionnaire dubbed QASICC (Questionnaire for Acceptance of and Satisfaction with Implanted Central Venous Catheter) assessing patient's satisfaction with and acceptance of their TIVAD; (ii) develop a mean score of patient's acceptance and satisfaction; (iii) look for correlation between QASICC score and TIVAD patient/tumor pathology/device characteristics. METHODS: From 2011 November to 2012 December, the first version of the QASICC questionnaire that included 27 questions assessing seven dimensions was re-tested among 998 cancer patients in eleven French cancer hospitals (eight cancer research institutes and three university/general hospitals). The goal was: (i) to reduce the questionnaire item and dimension number (pertinency, saturation effect, item correlation); (ii) to assess its psychometric properties, demonstrate its validity and independency compared to (EORTC) QLQC30; (iii) to correlate clinical and pathological patient's/tumor's/TIVAD's parameters with the QASICC questionnaire score (the higher the overall score, the greater the acceptance and satisfaction). The questionnaire was administered to the patient 30 days (±15 days) after TIVAD's implantation. RESULTS: Among 998 questionnaires given to cancer patients, 658 were analyzed and 464 were fully assessed as there was no missing data. Time to fill-in the questionnaire was five minutes in 90% patients. Final QASICC tool included twenty-two questions assessing four homogeneous dimensions (65%

Subject(s)
Catheterization, Central Venous/psychology , Central Venous Catheters , Patient Satisfaction , Surveys and Questionnaires , Activities of Daily Living , Female , France , Humans , Male , Pain/psychology , Privacy
10.
Int J Gynecol Cancer ; 24(9): 1675-8, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25340292

ABSTRACT

The purpose of this study is to review the available evidence documenting the prognostic role of adherence to guidelines in gynecologic cancers. A systematic review of the PubMed database using "guideline," "adherence," and "cancer" was carried out on February 25, 2014. Two thousand one hundred twenty-three publications were identified. Only publications addressing the question of adherence to recommendations regarding surgical care and multidisciplinary management of gynecologic cancers were selected. Six studies were identified in endometrial cancer, 4 in ovarian cancer, and none in cervical cancer. Adoption of guidelines is an effective tool for disease control and must consequently be considered as a process measure of quality cancer care. It is urgent to develop reliable and reproducible tools to assess adherence to guidelines based on level 1 evidence in gynecologic cancer then to carry out investigations to document the prognostic impact of compliance with guidelines. The time has come to include adherence to guidelines in quality assurance programs.


Subject(s)
Genital Neoplasms, Female/surgery , Guideline Adherence , Gynecologic Surgical Procedures , Practice Guidelines as Topic , Female , Humans , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL